GSK’s Arexvy vaccine for RSV is approved for Malaysian seniors
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine will be available in October 2024
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The results will support regulatory submissions to the FDA and EMA.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
The Financial Times2d
GSK’s ex-vaccines chief says its jab for a flu-like virus is too expensive
The first RSV vaccines were approved in the US in May last year. GSK’s Arexvy vaccine generated more than $1bn in sales ...
GlobalData on MSN1d
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I
UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...
Managed Healthcare Executive1d
RSV Vaccine Keeps Older People Out of the Hospital
Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...
FierceBiotech1d
Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1
The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...
The American Journal of Managed Care7d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
Moderna forecasts lower sales next year, shares near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
Health.com on MSN11d
Guide to 2024 Fall Vaccines: When to Get Your COVID, Flu, and RSV Shots
Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...